Propensity score matched analysis for the safety and effectiveness of remdesivir in COVID-19 patients with renal impairment

Abstract Backgrounds Remdesivir (RDV) is an antiviral agent approved for the treatment of coronavirus disease 2019 (COVID-19); however, is not recommended for patients with renal impairment. Due to limitations associated with prospective clinical trials, real-world data on the safety and efficacy of...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Eunmi Yang, Han Zo Choi, Subin Kim, Dong Hyun Oh, Mi Young Ahn, Sinyoung Ham, Eunyoung Lee, Jaehyun Jeon, Min-Kyung Kim, Hee-Chang Jang, Sang-Won Park, Jae-Phil Choi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2024-01-01
Serie:	BMC Infectious Diseases
Soggetti:	Remdesivir COVID-19 Renal insufficiency Propensity Score Safety
Accesso online:	https://doi.org/10.1186/s12879-023-08859-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!